Abstract
The rate of chemotherapy-induced ovarian failure (CIOF) has been reported as 14–100% and is age- and agent-dependent. The role of GnRH analogs (GnRHa) and oral contraceptives (OC) in the prevention of CIOF is questionable. We performed a systematic review and a meta-analysis of studies assessing the efficacy of hormonal interventions in reducing CIOF in cancer or systemic lupus erythematosus (SLE) patients treated with chemotherapy. MEDLINE, EMBASE, and conference proceedings were searched until October 2009. From 504 potentially relevant references, 21 comparative studies were included for review and analysis. Data were collected to determine the risk ratio (RR) for amenorrhea, FSH levels, pregnancy rate, and biomarkers for ovarian reserve. Sixteen studies (SLE: 4 studies, 85 patients; malignancy: 12 studies, 596 patients) which assessed GnRHa for fertility preservation prior to chemotherapy were included in the meta-analysis. Five studies which evaluated the use of OC were systematically reviewed. Meta-analysis revealed that GnRHa are effective in reducing amenorrhea rates in all patients (RR 0.26, 95% CI 0.14–0.49). Pregnancy rate was higher in the GnRHa arm. The advantage of GnRHa was shown only in observational studies, but not in randomized controlled trials. Biomarkers for ovarian reserve were similar in both arms. Studies evaluating the efficacy of oral contraceptives in preserving ovarian function showed inconclusive results. GnRHa appears to improve menstruation resumption. Nevertheless, randomized prospective trials are less conclusive for their real value in conserving ovarian reserve and pregnancy. Large-scale prospective randomized trials are warranted to evaluate the role of GnRHa in preventing CIOF.
Similar content being viewed by others
References
Knobf MT (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11:96–110
Elis A, Tevet A, Yerushalmi R et al (2006) Fertility status among women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 47:623–627
Thewes B, Meiser B, Taylor A et al (2005) Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 23:5155–5165
Sonmezer M, Bang H, Oktay K (2008) GnRH analogues preserve gonadal function without preserving fertility? Oncologist 13:615–617
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K, American Society of Clinical Oncology (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931
Waxman JH, Ahmed R, Smith D et al (1987) Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 19:159–162
Blumenfeld Z, Avivi I, Linn S et al (1998) Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11:1620–1626
Blumenfeld Z, Shapiro D, Shteinberg M et al (2000) Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9:401–405
Pereyra Pacheco B, Mendez Ribas JM, Milone G et al (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 81:391–397
Petri M, Brodsky R, Jones R et al (2004) High dose cyclophosphamide can cause ovarian failure. Arthritis Rheum 50(Suppl 9):408
Blumenfeld Z, Eckman A (2005) Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 34:40–43
Dann EJ, Epelbaum R, Avivi I et al (2005) Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 20:2247–2249
Somers EC, Marder W, Christman GM et al (2005) Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52:2761–2767
Castelo-Branco C, Nomdedeu B, Camus A et al (2007) Use of gonadotropin releasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 87:703–706
Giuseppe L, Attilio G, Edoardo DN et al (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12:141–147
Azem F, Samara N, Cohen T et al (2008) Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin’s disease. J Assist Reprod Genet 25:535–538
Blumenfeld Z, Avivi I, Eckman A et al (2008) Gonadotropin-releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89:166–173
Cigni A, Faedda R, Atzeni MM et al (2008) Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature. Am J Kidney Dis 52:887–896
Ismail-Khan R, Minton S, Cox C et al (2008) Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. J Clin Oncol 26:(abstr 524)
Huser M, Crha I, Ventruba P et al (2008) Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 23:863–868
Badawy A, Elnashar A, El-Ashry M et al (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697
Nitzschke M, Raddatz J,Bohlmann MK et al (2010) GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients. Arch Gynecol Obstet 282(1):83–88
Sverrisdottir A, Nystedt M, Johansson H et al (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567
Whitehead E, Shalet SM, Blackledge G et al (1983) The effect of combination chemotherapy on ovarian function in women treated for Hodgkin’s disease. Cancer 52:988–993
Longhi A, Pignotti E, Versari M et al (2003) Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep 10:151–155
Behringer K, Breuer K, Reineke T et al (2005) Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23:7555–7564
Behringer K, Wildt L, Mueller H et al (2010) No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol (in press)
Del Mastro L, Catzeddu T, Boni L et al (2008) Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17:74–78
Franke HR, Smit WM, Vermes I (2005) Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin’s disease undergoing chemotherapy. Gynecol Endocrinol 20:274–278
Potolog-Nahari C, Fishman A, Cohen I (2007) Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females. Gynecol Endocrinol 23:290–294
Recchia F, Saggio G, Amiconi G et al (2006) Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 106:514–523
Teinturier C, Hartmann O, Valteau-Couanet D et al (1998) Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22:989–994
Crosignani PG, Ragni G, Lombroso GC et al (1988) Ovarian stimulation of IVF patients: effects of the reversible hypogonadotropic state induced by GnRH agonist. Hum Reprod 3:39–41
Lutchman Singh K, Muttukrishna S et al (2007) Predictors of ovarian reserve in young women with breast cancer. Br J Cancer 96:1808–1816
van Beek RD, van den Heuvel-Eibrink MM, Laven JS et al (2007) Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin’s lymphoma during childhood. J Clin Endocrinol Metab 92:3869–3874
Bukman A, Heineman MJ (2001) Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update 7:581–590
Berlin JA, Rennie D (1999) Measuring the quality of trials: the quality of quality scales. JAMA 282:1083–1084
Henderson J, Gray R, Brocklehurst P (2007) Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome. BJOG 114:243–252
Higgins JPT, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
Sklar CA, Mertens AC, Mitby P et al (2008) Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 98:890–896
Matsumoto M, Miyauchi M, Yamamoto N et al (2000) Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer. Breast Cancer 7:237–240
Meirow D (2000) Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 169:123–131
Ataya KM, McKanna JA, Weintraub AM et al (1985) Luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 45:3651–3656
Letterie GS (2004) Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 19:831–837
Imai A, Furui T (2007) Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues. J Obstet Gynaecol 27:20–24
Danforth DR, Arbogast LK, Friedman CI (2005) Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 83:1333–1338
Chapman RM, Sutcliffe SB, Malpas JS (1979) Cytotoxic induced ovarian failure in women with Hodgkin’s disease. I. Hormonal function. JAMA 242:1877–1881
Meistrich ML (1994) Failure to demonstrate hormonal protection of chemotherapy-induced fertility reduction in female rats. Reprod Toxicol 8:277–278
Hsueh AJ, McGee EA, Hayashi M et al (2000) Hormonal regulation of early follicle development in the rat ovary. Mol Cell Endocrinol 163:95–100
Meistrich ML, Shetty G (2008) Hormonal suppression for fertility preservation in males and females. Reproduction 136:691–701
Meirow D, Assad G, Dor J et al (2004) The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 19:1294–1299
Gupta RK, Flaws JA (2005) Gonadotropin-releasing hormone (GnRH) analogues and the ovary: do GnRH antagonists destroy primordial follicles? Fertil Steril 83:1339–1342
Adashi EY (1994) Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal ‘add-back’ paradigms. Hum Reprod 9:1380–1397
Nagy A, Schally AV (2005) Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 73:851–859
Meirow D, Rabinovici J, Katz D et al (2008) Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 1:1634–1641
Quaas AM, Ginsburg ES (2007) Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol 134:3–8
Porcu E, Venturoli S (2006) Progress with oocyte cryopreservation. Curr Opin Obstet Gynecol 18:273–279
Sharma R, Hamilton A, Beith J (2008) LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 8:CD004562
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
I. Ben-Aharon and A. Gafter-Gvili contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ben-Aharon, I., Gafter-Gvili, A., Leibovici, L. et al. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 122, 803–811 (2010). https://doi.org/10.1007/s10549-010-0996-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-010-0996-7